Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

New data indicate a targeted drug from Nuvalent could help patients with a rare lung cancer for whom other drugs stopped ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain lesions, zidesamtinib mounted a 48% intracranial ORR, including 20% ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

Company to host webcast and conference call on June 24, 2025 at 8:00am ET CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company ...

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

Nuvalent (NASDAQ:NUVL) reported promising results from its mid-stage trial for zidesamtinib, a new drug that specifically targets ROS1, in patients with advanced ROS1-positive non-small cell lung ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares.

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to find out why NUVB stock is a Hold.

About ROS1+ NSCLC. Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.